statnews.com·Apr 30, 2026
A new obesity drug, described as a "quintuple agonist," has shown remarkable effectiveness in preclinical trials with mice, potentially surpassing existing GLP-1 treatments. Additionally, the funding landscape for NIH grants has become increasingly competitive, with only 13% of applications being funded last year.
The "quintuple agonist" obesity drug showing super effectiveness in mice is a key development to monitor. While still in preclinical stages, it represents a significant potential advancement over current GLP-1 based treatments. For professionals in healthtech and biotech, this drug could signal future investment opportunities or partnerships, particularly if it progresses to human trials and shows similar efficacy.